Navigation Links
AngelMD Investor Group Closes Second Round of Funding in Noninvasix
Date:1/8/2019

Today AngelMD announced that it completed a syndicate investment comprised of its members into Noninvasix. This represents the second investment AngelMD has made into Noninvasix in the past year.

To reduce the incidence of neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively measure brain oxygenation in preterm babies in the NICU. Early detection of inadequate brain oxygenation will allow neonatologists to intervene before cerebral function is permanently compromised.

Leading the AngelMD syndicate of investors was Jagjit Khairah, DO, FACOG, Department of Obstetrics & Gynecology, Kelsey Seybold Clinic who had this to say about Noninvasix: “The technological advances used with by Noninvasix to detect levels of oxygenation without needing a blood sample is remarkable. To have instant results using acoustic and laser sensor related probes will enable health care teams across many specialties of medicine to expedite critical care. Graham and his team have an amazing vision and are poised to help us change the way we address the needs of our patients on many fronts using this innovative technology.”

“Raising money through AngelMD is basically raising money from our future users. These are the people who understand best how Noninvasix’s technology can be a solution to some of their biggest issues.” said Graham Randall, CEO Noninvasix. “While we value all capital investment, having a group of engaged and supportive physicians backing us brings value well beyond the money.”

About Noninvasix

Noninvasix is developing non-invasive precision oximetry, which will allow doctors for the first time to accurately monitor oxygen sufficiency within organs without invasive catheters. Inadequate organ oxygenation is a major cause of death and permanent disability in hospitals. Prompt recognition of low venous oxygenation can be used to guide therapeutic interventions and reduce adverse outcomes.

With patented optoacoustic technology at its core, Noninvasix’s system consists of a disposable probe that can be worn on the head, chest or wrist — depending on the desired metric — and a display console.

Noninvasix's undertaking is backed by 15 years of optoacoustic research by its co-founders, more than $6.5 million in research grants, 9 patents, and validation in peer-review journal articles.

For more information, visit http://noninvasix.com/

About AngelMD

AngelMD, an online Healthcare Investment and Innovation Marketplace, connects and engages a network of physicians, angel investors, early stage healthcare companies and subject matter experts through a powerful technology platform to create better outcomes for patients and investors. For more information, visit http://www.angelmd.co

Read the full story at https://www.prweb.com/releases/angelmd_investor_group_closes_second_round_of_funding_in_noninvasix/prweb16018138.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. angelMD Completes Investment in Bleeding Detection Medical Device Company
2. 3 angelMD Startups Make Livestrong Big C Semi-finals
3. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
4. Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
8. Capricor Therapeutics to Present at Two Investor Conferences in March
9. Relmada Therapeutics to Participate in BIO CEO and Investor Conference
10. Biotech Stocks on Investors Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics
11. Arcturus Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today announced ... candidate, code-named "KM-819." KM-819 is an orally active small molecule that is ... Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to ...
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection and desire to improve ... the European Union (EU) on the horizon, Jim Kasic, president and CEO of Boulder ... the EU Medical Device Regulation (MDR), digital health, and big data are just a ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
Breaking Biology Technology:
(Date:12/22/2018)... ... December 21, 2018 , ... ... and hosted the Boston Healthcare Drinks event featuring Helen Chen, Greater China Managing ... China.” , The discussion was moderated by patent attorney David J. Dykeman ...
(Date:12/19/2018)... (PRWEB) , ... December 19, 2018 , ... InTouchMD’s flagship ... innovative products in healthcare for 2018. , PM360 is featuring the recognition in ... products and services offered to the pharmaceutical and medical device industries. , “This ...
(Date:12/18/2018)... ... December 18, 2018 , ... ... cancers and other serious diseases, today announced the publication of an early feasibility ... treatment of rGBM. , The publication of the study, An Early Feasibility ...
Breaking Biology News(10 mins):